Dr. Bergantin received his academic education at EPM-UNIFESP (Brazil): biomedicine (2008), MSc (2010) and PhD (2014); with a research visiting period in UAM (Spain). His research involves cell signalling mediated by Ca2+ and cAMP, including its role in neuropsychopharmacology, autonomic and cardiovascular pharmacology, and cancer. Dr. Bergantin´s research work solved the enigma of the paradoxical effects produced by L-type Ca2+ channel blockers (CCB), which was published in Cell Calcium (JCR: 4.87) and achieved the position ´ScienceDirect TOP 25 Hottest Articles´ (ranked #1 on the TOP 25 for Cell Calcium, 2013). This discovery generated 17 articles published in international journals indexed in PubMed, in which 14 of them Dr. Bergantin is the sole author; e.g. Cancer Letters (JCR: 7.36), Pharmacological Research (JCR: 5.89), Current Protein & Peptide Science (JCR: 2.52), Current Pharmaceutical Design (JCR: 2.20), Psychiatry Research (JCR: 2.11), Anti-Cancer Agents in Medicinal Chemistry (JCR: 2.04). Briefly, since 1975 several clinical and experimental studies have reported that acute and chronic administration of L-type CCB, such as nifedipine, produces reduction in arterial pressure associated with a paradoxical increase of sympathetic activity. In 2013, Dr. Bergantin discovered that this paradoxical increase in sympathetic activity produced by L-type CCB is due to the interaction of Ca2+/cAMP signalling, then opening new avenues for biomedical research, e.g. neurological and psychiatry diseases, cancer, diabetes, and asthma. Dr. Bergantin is member of several editorial boards of international journals, and has been frequently invited to be honorable guest in international conferences as well as to participating in media interviews. His last book is entitled ´The “Calcium Paradox” and its Impact on Neurological and Psychiatric Diseases´ (publisher: Cambridge Scholars Publishing. NLM ID: 101734546).